Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management
Author(s)
Bjoern Schwander, BSc, MA, RN, PhD1, Kirk W. Kerr, PhD2, Ricardo Rueda, PhD3, Maria Camprubi-Robles, PhD3, Suela Sulo, PhD4, Carl Lumsden, None5, Nicky Northway, None5, Louise Taylor, MA5.
1AHEAD GmbH, Bietigheim-Bissingen, Germany, 2Senior Manager, Abbott, Columbus, OH, USA, 3Abbott, Granada, Spain, 4Abbott, Northbrook, IL, USA, 5Changing Health, Uckfield, United Kingdom.
1AHEAD GmbH, Bietigheim-Bissingen, Germany, 2Senior Manager, Abbott, Columbus, OH, USA, 3Abbott, Granada, Spain, 4Abbott, Northbrook, IL, USA, 5Changing Health, Uckfield, United Kingdom.
OBJECTIVES: The RESET program seeks sustainable weight reduction and type 2 diabetes management in people with both diabetes and obesity, a high-risk group for diabetes-related complications. This is achieved through a low-calorie diet, including diabetes-specific nutritional formula (Glucerna®) and support and coaching through a digitally enabled technology for patient monitoring. During the initial weight-loss phase, patients reduced weight and improved diabetes risk factors. This health economic model quantifies the preventive effects and cost-effectiveness.
METHODS: A cohort state transition (Markov) model quantified the impact of risk factor changes during the 3-month weight-loss phase on diabetes complications. Risk equations from the UK Prospective Diabetes Study Outcomes Model 2 calculated combined risk reductions for microvascular and macrovascular complications by comparing changes in risk parameters (BMI, blood pressure, and HbA1C) from baseline to the end of the weight-loss phase. The overall risk reduction in diabetes complications served as the primary effectiveness measure. Costs were evaluated from a UK healthcare payer perspective, considering all RESET study setup, and running costs to determine cost-effectiveness in terms of cost per percentage diabetes-related complication risk reduction.
RESULTS: During the RESET weight-loss phase, average improvements included decreased weight (-10.9 kg), BMI (-3.7 kg/m²), HbA1C (-10.7 mmol/mol), and diastolic (-4.5 mmHg) and systolic (-5.8 mmHg) blood pressure. At the end of this phase, RESET achieved a mean risk reduction of 15.6% per user across combined complications compared to baseline, with incremental total costs of £1,369. The cost-effectiveness ratio per 1% complication risk reduction per user was about £88, indicating significant economic viability, and was stable in sensitivity analyses.
CONCLUSIONS: The RESET program effectively reduced overall event risk by 15.6% while maintaining a cost-effective profile. The cost per 1% complication risk reduction supports its economic justification. Future analyses will explore the ongoing benefits of the RESET study to determine the sustainability of these outcomes.
METHODS: A cohort state transition (Markov) model quantified the impact of risk factor changes during the 3-month weight-loss phase on diabetes complications. Risk equations from the UK Prospective Diabetes Study Outcomes Model 2 calculated combined risk reductions for microvascular and macrovascular complications by comparing changes in risk parameters (BMI, blood pressure, and HbA1C) from baseline to the end of the weight-loss phase. The overall risk reduction in diabetes complications served as the primary effectiveness measure. Costs were evaluated from a UK healthcare payer perspective, considering all RESET study setup, and running costs to determine cost-effectiveness in terms of cost per percentage diabetes-related complication risk reduction.
RESULTS: During the RESET weight-loss phase, average improvements included decreased weight (-10.9 kg), BMI (-3.7 kg/m²), HbA1C (-10.7 mmol/mol), and diastolic (-4.5 mmHg) and systolic (-5.8 mmHg) blood pressure. At the end of this phase, RESET achieved a mean risk reduction of 15.6% per user across combined complications compared to baseline, with incremental total costs of £1,369. The cost-effectiveness ratio per 1% complication risk reduction per user was about £88, indicating significant economic viability, and was stable in sensitivity analyses.
CONCLUSIONS: The RESET program effectively reduced overall event risk by 15.6% while maintaining a cost-effective profile. The cost per 1% complication risk reduction supports its economic justification. Future analyses will explore the ongoing benefits of the RESET study to determine the sustainability of these outcomes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE390
Topic
Economic Evaluation
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Nutrition